Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío
  • Esperanza-Cebollada, Elena
  • Llop, Marta
  • Robledo, Cristina
  • Vicente-Garcés, Clara
  • Ortega Blanco, Margarita
Leucèmia limfoblàstica aguda infantil; Seqüenciació de nova generació, Leucemia linfoblástica aguda infantil; Secuenciación de nueva generación, Childhood acute lymphoblastic leukemia; Next-generation sequencing, The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology’s complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice., This study has been supported by a grant from “Fundación Unoentrecienmil”; grants from Instituto de Salud Carlos III (PI12/02417; PI16/00246; PI12/00816; PI16CIII/00026; PI16/0665); Asociación Pablo Ugarte (TPY-M 1149/13; TRPV 205/18), ASION (TVP 141/17); Fundación Sonrisa de Alex & Todos somos Iván (TVP 1324/15); Consejería de Educación, Junta de Castilla y León (SA271P18); Fondos FEDER (CIBERONC [CB16/12/00284]), Proyectos de Investigación del SACYL, GRS 1847/A/18, Generalitat Valenciana GV2019/077 and Fundación AMPILE. J.M.H.S. is supported with a research grant by FEHH (“Fundación Española de Hematología y Hemoterapia”), A.M. a grant from Junta provincial de Salamanca de la Asociación Española Contra el Cáncer (AECC), and M.M. holds the grant “Ayuda predoctoral de la Junta de Castilla y León” by the Fondo Social Europeo (JCYL-EDU/556/2019 Ph.D. scholarship).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío|||0000-0001-9781-4198
  • Esperanza-Cebollada, Elena|||0000-0001-5451-0370
  • Llop, Marta
  • Robledo, Cristina|||0000-0003-0445-3210
  • Vicente-Garcés, Clara|||0000-0002-2556-043X
  • Alonso, Javier|||0000-0002-6287-8391
  • Barragán, Eva
  • Fernández, Guerau
  • Hernández-Sánchez, Jesús M.
  • Martín-Izquierdo, Marta
  • Maynou, Joan
  • Minguela, Alfredo|||0000-0003-2472-5893
  • Montaño, Adrián|||0000-0002-3178-6726
  • Ortega, Margarita
  • Torrebadell, Montserrat
  • Cervera, José|||0000-0001-8252-1106
  • Sánchez, Joaquín
  • Jiménez-Velasco, Antonio|||0000-0001-6421-7872
  • Riesco, Susana
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Lassaletta, Álvaro|||0000-0003-2881-1473
  • Fernández, José María
  • Rives, Susana|||0000-0002-5658-1831
  • Dapena, José Luis|||0000-0002-6711-7479
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Camós, Mireia|||0000-0003-3658-7942
The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology's complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (Oncomine TM Childhood Cancer Research Assay; Archer ® FusionPlex ® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2 ®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment

  • Vega-García, Nerea
  • Perez-Jaume, Sara
  • Esperanza-Cebollada, Elena|||0000-0001-5451-0370
  • Vicente-Garcés, Clara|||0000-0002-2556-043X
  • Torrebadell, Montserrat
  • Jiménez-Velasco, Antonio|||0000-0001-6421-7872
  • Ortega-Blanco, Margarita
  • Llop, Marta
  • Abad, Lorea
  • Vagace Valero, José Manuel|||0000-0001-8751-4319
  • Minguela, Alfredo|||0000-0003-2472-5893
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Sánchez-Garcia, Joaquin
  • García-Calderón, Clara B.
  • Gómez-Casares, María Teresa
  • Martín-Clavero, Estela
  • Escudero, Adela
  • Riñón Martinez-Gallo, Marta
  • Muñoz, Luz
  • Velasco, María Rosario
  • García-Morin, Marina|||0000-0003-1405-2912
  • Català, Albert|||0000-0003-0133-1752
  • Pascual, Antonia
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Fernández, José María
  • Lassaletta, Álvaro|||0000-0003-2881-1473
  • Fuster, José Luis|||0000-0002-4881-9440
  • Badell Serra, Isabel|||0000-0001-6546-2175
  • Molinos-Quintana, Águeda
  • Molinés, Antonio
  • Guerra-García, Pilar
  • Pérez Martínez, Antonio|||0000-0002-6436-9195
  • García-Abós, Miriam
  • Robles Ortiz, Reyes
  • Pisa Gatell, Sandra
  • Adán, Rosa
  • Díaz de Heredia, Cristina|||0000-0001-8086-296X
  • Dapena, José Luis|||0000-0002-6711-7479
  • Rives, Susana|||0000-0002-5658-1831
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Camós, Mireia|||0000-0003-3658-7942
Robust and applicable risk-stratifying genetic factors at diagnosis in pediatric T-cell acute lymphoblastic leukemia (T-ALL) are still lacking, and most protocols rely on measurable residual disease (MRD) assessment. In our study, we aimed to analyze the impact of NOTCH1, FBXW7, PTEN, and RAS mutations, the measurable residual disease (MRD) levels assessed by flow cytometry (FCM-MRD) and other reported risk factors in a Spanish cohort of pediatric T-ALL patients. We included 199 patients treated with SEHOP and PETHEMA consecutive protocols from 1998 to 2019. We observed a better outcome of patients included in the newest SEHOP-PETHEMA-2013 protocol compared to the previous SHOP-2005 cohort. FCM-MRD significantly predicted outcome in both protocols, but the impact at early and late time points differed between protocols. The impact of FCM-MRD at late time points was more evident in SEHOP-PETHEMA 2013, whereas in SHOP-2005 FCM-MRD was predictive of outcome at early time points. Genetics impact was different in SHOP-2005 and SEHOP-PETHEMA-2013 cohorts: NOTCH1 mutations impacted on overall survival only in the SEHOP-PETHEMA-2013 cohort, whereas homozygous deletions of CDKN2A/B had a significantly higher CIR in SHOP-2005 patients. We applied the clinical classification combining oncogenetics, WBC count and MRD levels at the end of induction as previously reported by the FRALLE group. Using this score, we identified different subgroups of patients with statistically different outcome in both Spanish cohorts. In SHOP-2005, the FRALLE classifier identified a subgroup of high-risk patients with poorer survival. In the newest protocol SEHOP-PETHEMA-2013, a very low-risk group of patients with excellent outcome and no relapses was detected, with borderline significance. Overall, FCM-MRD, WBC count and oncogenetics may refine the risk-stratification, helping to design tailored approaches for pediatric T-ALL patients.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío
  • Esperanza-Cebollada, Elena
  • Llop, Marta
  • Robledo, Cristina
  • Vicente-Garcés, Clara
  • Ortega Blanco, Margarita
Leucèmia limfoblàstica aguda infantil; Seqüenciació de nova generació, Leucemia linfoblástica aguda infantil; Secuenciación de nueva generación, Childhood acute lymphoblastic leukemia; Next-generation sequencing, The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology’s complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice., This study has been supported by a grant from “Fundación Unoentrecienmil”; grants from Instituto de Salud Carlos III (PI12/02417; PI16/00246; PI12/00816; PI16CIII/00026; PI16/0665); Asociación Pablo Ugarte (TPY-M 1149/13; TRPV 205/18), ASION (TVP 141/17); Fundación Sonrisa de Alex & Todos somos Iván (TVP 1324/15); Consejería de Educación, Junta de Castilla y León (SA271P18); Fondos FEDER (CIBERONC [CB16/12/00284]), Proyectos de Investigación del SACYL, GRS 1847/A/18, Generalitat Valenciana GV2019/077 and Fundación AMPILE. J.M.H.S. is supported with a research grant by FEHH (“Fundación Española de Hematología y Hemoterapia”), A.M. a grant from Junta provincial de Salamanca de la Asociación Española Contra el Cáncer (AECC), and M.M. holds the grant “Ayuda predoctoral de la Junta de Castilla y León” by the Fondo Social Europeo (JCYL-EDU/556/2019 Ph.D. scholarship).